Sensus Healthcare to Host Third Quarter 2022 Financial Results and Business Update Conference Call on November 3, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BOCA RATON, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 3, 2022 at 4:30 p.m. Eastern time to discuss the financial results for the third  quarter of 2022. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

To access the conference call, the dial-in numbers are 866-777-2509 (U.S. and Canada Toll Free), 412-317-5413 (International). Please direct the operator to be connected to the Sensus Healthcare conference call. The call will be webcast live and can be accessed at the following link, which also may be found in the Investor Relations section of the Company’s website at www.sensushealthcare.com.

Following the conclusion of the conference call, a replay will be available until December 3rd, and can be accessed by dialing 877-344-7529 (U.S. Toll Free), 855-669-9658 (Canada Toll Free), or 412-317-0088 (International).  At the system prompt, dial the replay code – 4619519 followed by the # sign. Playback will automatically begin. An archived webcast of the call will also be available in the Investor Relations section of the Company’s website for a period of time.

About Sensus Healthcare, Inc.

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

For more information, visit www.sensushealthcare.com.

Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com

# # #

Staff

Recent Posts

Endogenex Highlights 48-Week REGENT-1 Clinical Study Results at Digestive Disease Week 2025

Novel Endoscopic Procedure Demonstrates Substantial and Durable Reduction in Insulin Resistance and Improvement in Beta…

11 hours ago

SlimJaro Canada, Australia, UK, Reviews, Official Website, Discount Code, Trustpilot Complaints

Slimjaro Slimjaro Lakeland, FL, May 03, 2025 (GLOBE NEWSWIRE) -- SlimJaro Canada: The Revolutionary Fat-Burning…

11 hours ago

Javy Protein Coffee Under Review: Best Protein Coffee with Premium Ingredients by Javy Protein Coffee

Discover why Javy Protein Coffee is the best protein coffee for energy, recovery, and flavor.…

11 hours ago

Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08

PURCHASE, N.Y., May 02, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader…

11 hours ago

INP and Fight For Life Club Foundation Make History: Two Pediatric Living Donor Liver Transplants in One Week

Dallas, Texas, May 02, 2025 (GLOBE NEWSWIRE) -- In a historic medical achievement, the National…

11 hours ago

RaySearch Laboratories and Vision RT present innovations in surface guided treatment planning at ESTRO

STOCKHOLM, May 3, 2025 /PRNewswire/ -- At this week's ESTRO conference in Vienna, RaySearch Laboratories…

14 hours ago